POS0611 ONE YEAR PERSISTENCE AND EFFECTIVENESS OF GUSELKUMAB OR TNFi AS SECOND-LINE TREATMENT AFTER RECEIVING A TNFi AS FIRST-LINE THERAPY TO TREAT ACTIVE PSORIATIC ARTHRITIS: MANHATTAN STUDY | Publicación